No changes in serum concentrations of interleukin 10 (IL-10) and interferon gamma (IF-gamma) before and after treatment of the thyroid eye disease (TED).
TED is a severe eye disease leading in rare cases to decrease of sight, optic nerve compression and blindness. Recently, significant progresses in understanding the disease have been done. Nevertheless, the treatment of the disease, especially in its severe form remains challenging. Glucocorticoids (GC) have been the basis of the treatment for a long time. Orbital irradiation (OI) and optical decompression (OD) are also used in managing the severe forms of TED. Somatostatin, intravenous immunoglobulin have been also used, with conflicting results. Regarding the potential for the treatment of TED with cytokine antagonists, controlled clinical studies are not available. Since cytokines play an important role in the pathogenesis of the TED, they seemed to be logical choice for modern TED treatment. It has been shown that both Th1 (interleukin-2, tumor necrosis factor gamma, interleukin gamma) and Th2 (interleukin -4, -5, -10) profile T cells are activated in the TED. We therefore measured interleukin-gamma, IF-gamma and interleukin -10 (IL-10)(Th1 and Th2 pattern) to assess its relationship to the course of the disease. This paper shows that both Th1 (IL-2) and Th2 (IF-gamma) pathways represented by those two cytokines are not involved (IL-10 before 2.29+/-5.23 and after treatment 3.77+/-8.44; IF gamma before 0.50+/-0.24 and after treatment 0.35+/-0.19). No relationship to the response to treatment was found. GC resulted in positive response in 8/22 patients, OI (12 patients) given after CS therapy, resulted in a response in all patients. Increase in proptosis, loss of visual acuity is spite of CS treatment prompted OD in two patients, who both recovered visual acuity and proptosis fell under 25 mm Hertel.
Laban-Guceva
Nevenka
N
Clinic for Endocrinology, Metabolism and Diabetes, Faculty of Medicine, St. Cyril and Methodius University of Skopje, 50 Divizija bb, 1000 Skopje, Macedonia.
Antova
Magdalena
M
Bogoev
Milco
M
D017209:Apoptosis; D015415:Biomarkers; D016207:Cytokines / Q000378:metabolism; D005938:Glucocorticoids / Q000378:metabolism; D049970:Graves Ophthalmopathy / Q000097:blood*; D006801:Humans; D007249:Inflammation; D007371:Interferon-gamma / Q000097:blood* / Q000378:metabolism; D016753:Interleukin-10 / Q000097:blood*; D015999:Multivariate Analysis; D018417:Th1 Cells / Q000378:metabolism; D018418:Th2 Cells; D013974:Thyroxine / Q000378:metabolism
D015415:Biomarkers; D016207:Cytokines; D005938:Glucocorticoids; D016753:Interleukin-10; D007371:Interferon-gamma; D013974:Thyroxine